我们能否明确降低尿酸盐治疗在慢性肾脏疾病中的作用？

IF 14.8 1区医学 Q1 UROLOGY & NEPHROLOGY

Kidney international Pub Date : 2025-02-19 DOI:10.1016/j.kint.2024.11.025

Austin G. Stack

{"title":"我们能否明确降低尿酸盐治疗在慢性肾脏疾病中的作用？","authors":"Austin G. Stack","doi":"10.1016/j.kint.2024.11.025","DOIUrl":null,"url":null,"abstract":"<div><div>The therapeutic value of serum urate lowering in chronic kidney disease is questionable given the lack of clinical benefit from randomized clinical trials. <em>Post hoc</em> analysis of the CARES (Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities) trial suggests a protective effect of urate lowering in gout participants over 2.5 years of follow-up with the greatest benefit for those who maintained average urate levels of <6 mg/dl. A shift in research focus from asymptomatic hyperuricemia to symptomatic hyperuricemia may yet yield dividends.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"107 3","pages":"Pages 394-396"},"PeriodicalIF":14.8000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can we crystallize the role of urate-lowering treatment in chronic kidney disease?\",\"authors\":\"Austin G. Stack\",\"doi\":\"10.1016/j.kint.2024.11.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The therapeutic value of serum urate lowering in chronic kidney disease is questionable given the lack of clinical benefit from randomized clinical trials. <em>Post hoc</em> analysis of the CARES (Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities) trial suggests a protective effect of urate lowering in gout participants over 2.5 years of follow-up with the greatest benefit for those who maintained average urate levels of <6 mg/dl. A shift in research focus from asymptomatic hyperuricemia to symptomatic hyperuricemia may yet yield dividends.</div></div>\",\"PeriodicalId\":17801,\"journal\":{\"name\":\"Kidney international\",\"volume\":\"107 3\",\"pages\":\"Pages 394-396\"},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2025-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney international\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0085253824008627\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0085253824008627","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

由于缺乏随机临床试验的临床获益，血清尿酸降低对慢性肾脏疾病的治疗价值值得怀疑。对CARES（非布司他和别嘌呤醇在痛风和心血管疾病患者中的心血管安全性）试验的事后分析表明，在2.5年的随访中，降低痛风参与者的尿酸水平具有保护作用，那些保持平均尿酸水平为6mg /dl的人获益最大。将研究重点从无症状高尿酸血症转移到有症状的高尿酸血症可能还会产生红利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Can we crystallize the role of urate-lowering treatment in chronic kidney disease?

The therapeutic value of serum urate lowering in chronic kidney disease is questionable given the lack of clinical benefit from randomized clinical trials. Post hoc analysis of the CARES (Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities) trial suggests a protective effect of urate lowering in gout participants over 2.5 years of follow-up with the greatest benefit for those who maintained average urate levels of <6 mg/dl. A shift in research focus from asymptomatic hyperuricemia to symptomatic hyperuricemia may yet yield dividends.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Kidney international 医学-泌尿学与肾脏学

CiteScore

23.30

自引率

3.10%

发文量

490

审稿时长

3-6 weeks

期刊介绍： Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.